register

News & Trends - Pharmaceuticals

Daiichi Sankyo expands local footprint

Health Industry Hub | February 26, 2024 |

Pharma News: Daiichi Sankyo has welcomed Dr Mark Rutstein, Head of Global Oncology Clinical Development, for a week-long visit. This marks the third visit from a global executive in as many months, underlining the company’s dedication to expanding its footprint in Australia.

During his visit, Dr Rutstein engaged in insightful discussions with leading cancer researchers and experts in Sydney and Melbourne. The primary focus was on ongoing research and development, addressing critical evidence gaps encountered in their work, and exploring avenues for further collaboration.

Dr Rutstein expressed his enthusiasm for the trip, stating “I’ve been wanting to come back to Australia for a while now. The trip has been a tremendous opportunity to both meet with the local team and world-class oncology researchers.”

He highlighted Australia’s significance as a market for Daiichi Sankyo, emphasising the extensive collaboration on DXd antibody drug conjugate (ADC) candidates. Currently, the company is actively involved with more than 40 sites across Australia, conducting 10 trials to evaluate DXd ADC technology, with plans for additional trials in the future.

Masaaki Kotaki, Managing Director of Daiichi Sankyo Australia, reflected on the significance of Dr Rutstein’s visit.

“We were honoured to host Dr Rutstein, our company’s third global leader to visit since we officially inaugurated Daiichi Sankyo Australia. The visit is further testament to our commitment to collaborating with Australia’s leading research community to develop the next generation of cancer medicines,” he said.

The visit coincides with Daiichi Sankyo’s ongoing expansion of its local team in Australia. Since January, seven new members have joined the Australian business, with plans for further expansion, including the introduction of field-based commercial team members, Medical Science Liaisons (MSLs), and a Human Resources (HR) generalist.

Mr Kotaki expressed confidence in the company’s growth, stating “With the strong global backing and successful launch of the Australian team in 2023, we are proud to continue to grow our local team. We have recruited exceptional talent who are committed to making a meaningful difference to patients with cancer in Australia.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.